LIXTE Biotechnology acquires Liora Technologies for cancer treatment technology.

LIXTE Biotechnology Holdings has acquired UK-based Liora Technologies Europe Ltd., a company pioneering electronically controlled proton therapy systems for treating various types of cancers. Liora's LiGHT System provides significant advantages over current technologies for proton therapy. The LiGHT system is installed at STFC's Daresbury Laboratory, which will provide resources to develop a center of excellence for proton therapy. The acquisition includes $300+ million invested to date in developing the technology.